NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: IPSEN Group
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP) - Ipsen to present new insights at ASBMR for potential treatment of ultra-rare disease fibrodysplasia ossificans progressiva (FOP), including global Phase III MOVE trial results - ASBMR.org / IPSEN.com
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)

 

NewswireToday - /newswire/ - Paris, Ile-de-France, France, 2020/09/11 - Ipsen to present new insights at ASBMR for potential treatment of ultra-rare disease fibrodysplasia ossificans progressiva (FOP), including global Phase III MOVE trial results - ASBMR.org / IPSEN.com. Euronext: IPN; ADR: IPSEY

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

• Seven presentations represent Ipsen’s largest presence to date at ASBMR (asbmr.org), the world’s leading scientific organization for bone health research;
• Ipsen’s data demonstrate potential advances in understanding fibrodysplasia ossificans progressiva (FOP), including key learnings related to study design, natural history, biomarkers, investigational therapeutic options, and disease-specific patient-reported outcome measures.

Ipsen announced that it will share data from the company’s growing Rare Diseases Therapeutic Area portfolio, with seven presentations at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting (September 11-15, 2020). These include the oral presentation of Ipsen’s MOVE trial (during the Novel Therapies for Rare Bone Disease session on Saturday, 12 September [11:00am 12:15pm ET]), the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva (FOP). The data will be presented by Dr Robert Pignolo, Division of Geriatric Medicine and Gerontology, Department of Internal Medicine, Mayo Clinic, and describes the trial outcomes of the oral investigational therapy palovarotene in reducing new heterotopic ossification (HO) volume in 107 pediatric and adult patients with FOP.1 The MOVE efficacy results were compared with data from untreated patients from Ipsen’s Natural History Study (NHS).2 Safety outcomes from the MOVE trial will also be presented.

“Our passion and commitment to understanding rare diseases has driven this research forward and we’re proud to present these data at the ASBMR 2020 Annual Meeting,” said Howard Mayer, M.D., Executive Vice President and Head of Research and Development at Ipsen. “Collaboration is critical with rare disease research and development and we look forward to continuing to work with key thought leaders, clinicians, the patient advocacy community, and regulatory authorities as we build on our research and develop potential therapeutic agents in rare diseases, including for patients with FOP.”

Additionally, four posters reporting data from the NHS will be presented. The NHS is the largest FOP study of this kind worldwide and is the first global, multicenter, longitudinal study designed to measure disease progression over three years.2 Findings from the NHS reinforce that measuring HO is a viable way to monitor changes in FOP and to assess a potential treatment effect over this time period.

About Palovarotene

Palovarotene is an oral investigational, selective RARγ agonist being developed as a potential treatment for patients with the debilitating ultra-rare, genetic disorder fibrodysplasia ossificans progressiva (FOP). Palovarotene, which had rare pediatric disease and breakthrough therapy designations for the treatment of FOP, was acquired by Ipsen through the acquisition of Clementia Pharmaceuticals in April 2019.

About Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare, genetic disorder characterized by bone that forms outside the normal skeleton, in muscles, tendons or soft tissue.3 FOP is among the rarest of human diseases, and while there are approximately 1,000 described cases globally, the reported prevalence of FOP is estimated at approximately 1.36 per million individuals.4,5

About Ipsen

Ipsen (ipsen.com) is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas Oncology, Neuroscience, and Rare Diseases. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.5 billion in 2019, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,800 employees worldwide.

Contacts:
Media: Maryann Quinn - Director, Product Communications North America
P: +1 857-529-1151 - E: Maryann.quinn[.]ipsen.com.

Financial Community:
Eugenia Litz - Vice President, Investor Relations
P: +44(0)17 5362 7721 - E: eugenia.litz[.]ipsen.com.

Myriam Koutchinsky - Investor Relations Manager
P: +33(0)1 58 33 51 04 - E: myriam.koutchinsky[.]ipsen.com.

References

1. Pignolo R et al. Palovarotene (PVO) for fibrodysplasia ossificans progressiva (FOP): Data from the phase III MOVE trial. ASBMR September 2020.
2. Al Mukaddam M et al. A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 12-Month Outcomes. J Endocr Soc. 2020;4 (Supplement 1):OR29-05
3. The Medical Management of Fibrodysplasia Ossificans Progressiva: Current Treatment Considerations, IFOPA. Accessed: May 2020.
4. Lilijesthrom M & Bogard B. The Global Known FOP Population. Presented at the FOP Drug Development Forum. Boston, MA; 2016.
5. Baujat et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet Journal of Rare Diseases. 2017; 12:123.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: IPSEN Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Jess Smith - IPSEN.com 
+44(0)75 5726 7634 jess.smith[.]ipsen.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IPSEN Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From IPSEN Group / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

BASF and Evonik Partner to Reduce the Environmental Footprint of the Feed and Animal Protein Industries
Rely+On Virkon from LANXESS Effective Against Monkeypox Virus
DSM Completes Acquisition of Prodap
Bruker’s Arxspan Business for Lab Informatics Expands Customer Capabilities by Joining Tetra Partner Network
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-line Monotherapy for Small Cell Lung Cancer
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-oncology Candidates from Marengo’s STAR Platform
SCHOTT Establishes Stand-alone Company for its Pharma Business to Promote Further Growth
Bushu Pharma Lauded by Frost & Sullivan for Enabling the Launch of Specialty Drugs in Japan and Asia-Pacific
BASF Expands World-scale Vitamin A Formulation Plant in Ludwigshafen
Ipsen to Acquire Epizyme, Expanding its Portfolio in Oncology
ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
GenScript ProBio and ProteoNic BV Signed a Strategic Cooperation Based on High Expressing Vector System
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults
DSM Acquires Brazil’s Leading Animal Nutrition Technology Company to Boost Precision Services Offering
DSM and the World Food Programme Partner to Improve Nutrition Around the World

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Luxury Executive Wellness

Visit  JobsWare.com





 
  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)